← Search & browse all drugs

abrocitinib

D11AH08

Forms & Strengths

100mg and 200mg oral tablets
film-coated for oral administration

Adult Dosing

Initial dose 200mg once daily
may be reduced to 100mg once daily for certain adverse reactions

Pediatric Dosing

safety and efficacy not established in patients less than 12 years
for patients 12 years and older, same dosing as adults

Indications

treatment of moderate-to-severe atopic dermatitis
inadequate response to conventional therapies or when they are not feasible

Mechanism of Action

selective inhibitor of Janus kinase 1 (JAK1)
modulates immune response by inhibiting JAK1-dependent signaling

Contraindications

hypersensitivity to abrocitinib or any component of the formulation
active serious infections

Adverse Reactions

nasopharyngitis
natriuresis and subsequent decrease in creatinine clearance
elevations in LDL cholesterol

Drug Interactions

concomitant use with strong CYP2C19 inhibitors (e.g. fluconazole, proton pump inhibitors)
potential increased exposure to abrocitinib with CYP2C19 inhibitors

Curated Content: Needs Vetting Before Put to Clinical Use